Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. Quintarelli C, et al. Among authors: de angelis b. Blood. 2011 Mar 24;117(12):3353-62. doi: 10.1182/blood-2010-08-300376. Epub 2011 Jan 28. Blood. 2011. PMID: 21278353 Free PMC article.
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Perna SK, et al. Among authors: de angelis b. Clin Cancer Res. 2013 Jan 1;19(1):106-17. doi: 10.1158/1078-0432.CCR-12-2143. Epub 2012 Nov 13. Clin Cancer Res. 2013. PMID: 23149818 Free PMC article.
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.
Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F. Quintarelli C, et al. Among authors: de angelis b. Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15. Leuk Res. 2014. PMID: 24280282
Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C, Locatelli F, Caruana I, De Angelis B. Quintarelli C, et al. Among authors: de angelis b. Mol Ther. 2016 May;24(5):845-6. doi: 10.1038/mt.2016.72. Mol Ther. 2016. PMID: 27198849 Free PMC article. No abstract available.
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I. Bocca P, et al. Among authors: de angelis b. Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017. Oncoimmunology. 2017. PMID: 29296542 Free PMC article.
155 results